Seeking a potential breakthrough therapy for patients with
Complex Regional Pain Syndrome Type 1 (CRPS-1)
Overview
Ambros Therapeutics, headquartered in San Diego, California, is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases with a high unmet medical need.
Our lead investigational program targets complex regional pain syndrome type 1 (CRPS-1), a severely painful, debilitating orphan disease typically following a limb injury.
Patients may experience significant functional loss, sleep disturbance, and meaningful diminished quality of life and independence.
Ambros’ Phase 3 pivotal trial (CRPS-RISE) represents a potentially first-in-class approach to addressing a disease with no FDA-approved medicines.
What is Complex Regional Pain Syndrome Type 1?
Complex regional pain syndrome type 1 (CRPS-1) is a rare and debilitating condition following an injury or trauma to the bone. There are currently no FDA-approved medicines available to treat this high unmet need patient population.
Our Approach to CRPS-1 with Neridronate
Neridronate is a differentiated bisphosphonate with established efficacy in Italy in several bone diseases, including in CRPS-1. We believe its unique binding characteristics and pharmacologic profile allow for a balance of safety and efficacy compared to other bisphosphonates.
of neridronate in patients with CRPS-1 in the United States
Loading...